Hemoglobin A1c by immunoassay; estimated average glucose
Within 1 day
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Pediatric EDTA whole blood tubes may be used. Please place original labeled capillary tube in a labeled transport tube for shipment to the laboratory.
Lavender-top (EDTA) tube, green-top (lithium heparin) tube, or gray-top (sodium fluoride) tube
The usual precautions in the collection of venipuncture samples should be observed. The sample must be free of clots. Samples with any hematocrit disorders can lead to erroneous results. Send the entire tube to the laboratory.
Maintain specimen at room temperature.
Clotted specimen; gross hemolysis
Self-monitoring of blood glucose (SMBG) is one of the two primary techniques available for health providers and patients to assess the effectiveness of the management plan on glycemic control in diabetes. SMBG is typically carried out in the form of frequent fingerstick capillary glucose testing. Another more recent technology available is continuous glucose monitoring (CGM) carried out through a sensor that measures interstitial glucose concentration which correlates well with plasma glucose and capillary glucose levels. The second glycemic control technique is measurement of hemoglobin A1c (Hb A1c).
Because measurement of Hb A1c is primary, the most accurate glycemic control tool available, it is important to correlate Hb A1c results with ones obtained using SMBG for long-term metabolic control and management of diabetes. Recently, the international multicenter A1c-Derived Average Glucose (ADAG) trial successfully completed and results determined that the correlation between Hb A1c results and eAG (the new term used to combine both CGM and fingerstick capillary glucose testing) is strong enough to justify reporting of both an Hb A1c results and eAG result. This conclusion is endorsed by the American Diabetes Association (ADA) and the American Association of Clinical Chemists. The relationship is expressed in the following formula:
eAG(mg/dL) = 28.7 x Hb A1c(%) - 46.7
This relationship applies only to Hb A1c methods certified as traceable to DCCT reference, and is based on overall averages and may vary slightly in individual patients. LabCorp uses a DCCT traceable method.
Mean plasma glucose estimates outside of the 5.0% to 15.0% Hb A1c range are not calculated since estimations in the nondiabetic range have not been verified. Only diabetic patients in stable control and without any suggestion of erythrocyte disorders were entered into the study. Children and pregnant women were also excluded; additional data in these groups are needed to confirm the established relationship. This mean plasma glucose calculation should only be used with Hb A1c (001453). For additional information, see Hemoglobin (Hb) A1c .
Roche Tina Quant
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|102525||Hgb A1c with eAG Estimation||55399-0||001481||Hemoglobin A1c||%||4548-4|
|102525||Hgb A1c with eAG Estimation||55399-0||001472||Estim. Avg Glu (eAG)||mg/dL||27353-2|
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf